NMDA receptor activation regulates sociability by its effect on mTOR signaling activity

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 60, Issue , 2015, Pages 60-65

  Burket, Jessica A ^a   Benson, Andrew D ^a   Tang, Amy H ^a   Deutsch, Stephen I ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

D Cycloserine; mTOR; NMDA receptor; Sociability; Tuberous sclerosis

Indexed keywords

ARGININE; CYCLOSERINE; GLUTAMIC ACID; GLYCINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE; RAPAMYCIN; STRIATAL ENRICHED PROTEIN TYROSINE PHOSPHATASE; TUBERIN; UNCLASSIFIED DRUG; TARGET OF RAPAMYCIN KINASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTISM; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME PHOSPHORYLATION; INTELLECTUAL IMPAIRMENT; MOUSE; MOUSE MODEL; NMDA RECEPTOR ACTIVATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; TRANSGENIC MOUSE; TUBEROUS SCLEROSIS; ANIMAL; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; MICE; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 84923369865     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.02.009     Document Type: Review

References (58)

1. Benson A.D., Burket J.A., Deutsch S.I. Balb/c mice treated with D-cycloserine arouse increased social interest in conspecifics. Brain Res Bull 2013, 99:95-99. [Oct].
2. Billingslea E.N., Tatard-Leitman V.M., Anguiano J., Jutzeler C.R., Suh J., Saunders J.A., et al. Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2014, 39(7):1603-1613. [Jun].
3. Brodkin E.S. BALB/c mice: low sociability and other phenotypes that may be relevant to autism. Behav Brain Res 2007, 176(1):53-65. [Jan 10].
4. Brodkin E.S. Social behavior phenotypes in fragile X syndrome, autism, and the Fmr1 knockout mouse: theoretical comment on McNaughton et al. (2008). Behav Neurosci 2008, 122(2):483-489. [Apr].
5. Burket J.A., Cannon W.R., Jacome L.F., Deutsch S.I. MK-801, a noncompetitive NMDA receptor antagonist, elicits circling behavior in the genetically inbred Balb/c mouse strain. Brain Res Bull 2010 Nov 20, 83(6):337-339.
6. Burket J.A., Herndon A.L., Deutsch S.I. Locomotor activity of the genetically inbred Balb/c mouse strain is suppressed by a socially salient stimulus. Brain Res Bull 2010 Oct 30, 83(5):255-256.
7. Burket J.A., Benson A.D., Tang A.H., Deutsch S.I. D-Cycloserine improves sociability in the BTBR T+ Itpr3tf/J mouse model of autism spectrum disorders with altered Ras/Raf/ERK1/2 signaling. Brain Res Bull 2013, 96:62-70. [Jul].
8. Burket J.A., Benson A.D., Tang A.H., Deutsch S.I. Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders. Brain Res Bull 2014, 100:70-75. [Jan].
9. Buxbaum J.D., Hof P.R. The neuroscience of autism spectrum disorders 2012, Academic Press.
10. Cambiaghi M., Cursi M., Magri L., Castoldi V., Comi G., Minicucci F., et al. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. Neuropharmacology 2013, 67:1-7. [Apr].
11. Canitano R. New experimental treatments for core social domain in autism spectrum disorders. Front Pediatr 2014, 2:61.
12. Crino P.B. mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 2011, 17(12):734-742. [Dec].
13. Cuscó I., Medrano A., Gener B., Vilardell M., Gallastegui F., Villa O., et al. Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder. Hum Mol Genet 2009, 18(10):1795-1804. [May 15].
14. De Kleine R.A., Hendriks G.-J., Smits J.A.J., Broekman T.G., van Minnen A. Prescriptive variables for d-cycloserine augmentation of exposure therapy for posttraumatic stress disorder. J Psychiatr Res 2014, 48(1):40-46. [Jan].
15. Deutsch S.I., Rosse R.B., Paul S.M., Riggs R.L., Mastropaolo J. Inbred mouse strains differ in sensitivity to "popping" behavior elicited by MK-801. Pharmacol Biochem Behav 1997, 57(1-2):315-317. [Jun].
16. Deutsch S.I., Mastropaolo J., Powell D.G., Rosse R.B., Bachus S.E. Inbred mouse strains differ in their sensitivity to an antiseizure effect of MK-801. Clin Neuropharmacol 1998, 21(4):255-257. [Aug].
17. Deutsch S.I., Burket J.A., Jacome L.F., Cannon W.R., Herndon A.L. D-Cycloserine improves the impaired sociability of the Balb/c mouse. Brain Res Bull 2011, 84(1):8-11. [Jan 15].
18. Deutsch S.I., Burket J.A., Urbano M.R., Herndon A.L., Winebarger E.E. Impaired sociability of the Balb/c mouse, an animal model of autism spectrum disorders, is attenuated by NMDA receptor agonist interventions: clinical implications. Compr Book Autism Spectr Disord [Internet] 2011, InTech, [Available from: http://www.intechopen.com/articles/show/title/impaired-sociability-of-the-Balb-c-mouse-an-animal-model-of-autism-spectrum-disorders-is-attenuated-]. M. Mohammad-Reza (Ed.).
19. Deutsch S.I., Pepe G.J., Burket J.A., Winebarger E.E., Herndon A.L., Benson A.D. D-cycloserine improves sociability and spontaneous stereotypic behaviors in 4-week old mice. Brain Res 2012, 1439:96-107. [Feb 23].
20. Difede J., Cukor J., Wyka K., Olden M., Hoffman H., Lee F.S., et al. D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2014, 39(5):1052-1058. [Apr].
21. Ehninger D. From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches. Neuropharmacology 2013, 68:97-105. [May].
22. Ehninger D., Silva A.J. Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol Med 2011, 17(2):78-87. [Feb].
23. Fitzpatrick C.J., Lombroso P.J. The role of striatal-enriched protein tyrosine phosphatase (STEP) in cognition. Front Neuroanat 2011, 5:47.
24. Garg S., Plasschaert E., Descheemaeker M.-J., Huson S., Borghgraef M., Vogels A., et al. Autism spectrum disorder profile in neurofibromatosis type I. J Autism Dev Disord 2014, 5. [Dec].
25. Goff D.C. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull 2012, 38(5):936-941. [Sep].
26. Goff D.C., Cather C., Gottlieb J.D., Evins A.E., Walsh J., Raeke L., et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008, 106(2-3):320-327. [Dec].
27. Halene T.B., Ehrlichman R.S., Liang Y., Christian E.P., Jonak G.J., Gur T.L., et al. Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav 2009, 8(7):661-675. [Oct].
28. Hoeffer C.A., Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 2010, 33(2):67-75. [Feb].
29. Huang Y., Kang B.N., Tian J., Liu Y., Luo H.R., Hester L., et al. The cationic amino acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycin mTOR pathway. J Neurosci 2007, 27(3):449-458. [Jan 17].
30. Jacome L.F., Burket J.A., Herndon A.L., Cannon W.R., Deutsch S.I. D-serine improves dimensions of the sociability deficit of the genetically-inbred Balb/c mouse strain. Brain Res Bull 2011, 84(1):12-16. [Jan 15].
31. Jacome L.F., Burket J.A., Herndon A.L., Deutsch S.I. D-Cycloserine enhances social exploration in the Balb/c mouse. Brain Res Bull 2011, 85(3-4):141-144. [May 30].
32. Jacome L.F., Burket J.A., Herndon A.L., Deutsch S.I. Genetically inbred Balb/c mice differ from outbred Swiss Webster mice on discrete measures of sociability: relevance to a genetic mouse model of autism spectrum disorders. Autism Res 2011, 4(6):393-400.
33. Jasien J.M., Daimon C.M., Wang R., Shapiro B.K., Martin B., Maudsley S. The effects of aging on the BTBR mouse model of autism spectrum disorder. Front Aging Neurosci 2014, 6:225.
34. Kim E., Wang Y., Kim S.-J., Bornhorst M., Jecrois E.S., Anthony T.E., et al. Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. eLife 2015, 4.
35. Labrie V., Lipina T., Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2008, 200(2):217-230. [Oct].
36. Levitt P., Campbell D.B. The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J Clin Invest 2009, 119(4):747-754. [Apr].
37. McAllister K.H. D-cycloserine enhances social behaviour in individually-housed mice in the resident-intruder test. Psychopharmacology (Berl) 1994, 116(3):317-325. [Nov].
38. McFarlane H.G., Kusek G.K., Yang M., Phoenix J.L., Bolivar V.J., Crawley J.N. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes Brain Behav 2008, 7(2):152-163. [Mar].
39. Meikle L., Talos D.M., Onda H., Pollizzi K., Rotenberg A., Sahin M., et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 2007, 27(21):5546-5558. [May 23].
40. Meikle L., Pollizzi K., Egnor A., Kramvis I., Lane H., Sahin M., et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008, 28(21):5422-5432. [May 21].
41. Millan M.J. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 2005, 179(1):30-53. [Apr].
42. Millan M.J., Fone K., Steckler T., Horan W.P. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2014, 24(5):645-692. [May].
43. Paul S., Connor J.A. NR2B-NMDA receptor-mediated increases in intracellular Ca2+ concentration regulate the tyrosine phosphatase, STEP, and ERK MAP kinase signaling. J Neurochem 2010, 114(4):1107-1118. [Aug].
44. Paul S., Nairn A.C., Wang P., Lombroso P.J. NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci 2003, 6(1):34-42. [Jan].
45. Peça J., Feng G. Cellular and synaptic network defects in autism. Curr Opin Neurobiol 2012, 22(5):866-872.
46. Sahin M. Targeted treatment trials for tuberous sclerosis and autism: no longer a dream. Curr Opin Neurobiol 2012, 22(5):895-901. [Oct].
47. Scheeringa M.S., Weems C.F. Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress. J Child Adolesc Psychopharmacol 2014, 24(2):69-77. [Mar].
48. Sharma A., Hoeffer C.A., Takayasu Y., Miyawaki T., McBride S.M., Klann E., et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010, 30(2):694-702. [Jan 13].
49. Silverman J.L., Tolu S.S., Barkan C.L., Crawley J.N. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2010, 35(4):976-989. [Mar].
50. Talos D.M., Sun H., Zhou X., Fitzgerald E.C., Jackson M.C., Klein P.M., et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One 2012, 7(5):e35885.
51. Tsai P.T., Hull C., Chu Y., Greene-Colozzi E., Sadowski A.R., Leech J.M., et al. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 2012, 488(7413):647-651. [Aug 30].
52. Urbano M., Okwara L., Manser P., Hartmann K., Herndon A., Deutsch S.I. A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder. Clin Neuropharmacol 2014, 37(3):69-72. [Jun].
53. Urbano M.R., Okwara L., Manser P., Hartmann K., Deutsch S.I. A trial of D-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders. J Neuropsychiatry Clin Neurosci 2015, [Apr] (in press).
54. Veenstra-Vanderweele J., Christian S.L., Cook E.H. Autism as a paradigmatic complex genetic disorder. Annu Rev Genomics Hum Genet 2004, 5:379-405.
55. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008, 165(3):335-341. [Mar. quiz 409].
56. Wöhr M., Roullet F.I., Crawley J.N. Reduced scent marking and ultrasonic vocalizations in the BTBR T+tf/J mouse model of autism. Genes Brain Behav 2011, 10(1):35-43. [Feb].
57. Won H., Lee H.-R., Gee H.Y., Mah W., Kim J.-I., Lee J., et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 2012, 486(7402):261-265. [June 14].
58. Yang M., Zhodzishsky V., Crawley J.N. Social deficits in BTBR T+tf/J mice are unchanged by cross-fostering with C57BL/6J mothers. Int J Dev Neurosci Off J Int Soc Dev Neurosci 2007, 25(8):515-521. [Dec].